Mallinckrodt Pharmaceuticals

Phone: +353353 1 6960000

Web: https://www.mallinckrodt.com

Type	public liability company
Traded as	{NYSE:American:MNK}
ISIN
Industry	Pharmaceutical
Predecessor	Mallinckrodt Inc. (before the 2013 tax inversion to Ireland)
Founded	1867 (1867)
Headquarters	(Legal) College Business & Technology Park, Cruiserath, Blanchardstown, D15 TX2V, Dublin, Ireland (Executive) 3 Lotus Park, The Causeway, Staines-upon-Thames, Surrey, United Kingdom (Operational) 675 McDonnell Boulevard, St Louis, Missouri, United States
Key people	Sigurdur (Siggi) Olafsson (CEO), Bryan Reasons (CFO)
Revenue	US$3.162 billion (2019)
Operating income	US$1.421 billion (2019)
Net income	−US$1.822 billion (2019)
Total assets	US$10.338 billion (2019)
Total equity	US$8.398 billion (2019)
Number of employees	3,400 (2019)
Website	mallinckrodt.com

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Managing Complexity. Improving Lives. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

For detailed contact information visit location pages below.